Chronic Obstructive Pulmonary Disease Drugs Market Size 2024-2028

The chronic obstructive pulmonary disease drugs market is estimated to grow by USD 7.19 billion at a CAGR of 6.24% between 2023 and 2028. Market growth depends on several factors, including the increasing incidence of chronic obstructive pulmonary disease, a robust pipeline of new drugs receiving approvals, and rising demand for fixed-dose combinations. The prevalence of COPD, a chronic inflammatory lung disease, is on the rise globally, driving the need for effective treatments. The pharmaceutical industry's focus on developing novel drugs and receiving regulatory approvals is fueling market expansion. Moreover, Chronic Obstructive Pulmonary Disease (COPD) drugs and Pulmonary Arterial Hypertension (PAH) drugs are both critical in managing severe respiratory conditions, as they target different aspects of lung and cardiovascular health. These efforts focus on diagnosis, recognition, and the development of diagnostic tools and treatments for COPD, including generic drugs. Additionally, the demand for fixed-dose combinations, which offer convenience and improved adherence, is growing. These factors collectively contribute to the market's growth trajectory, indicating a promising future for COPD therapeutics as they cater to the evolving needs of patients and healthcare providers.

What will be the size of the Market During the Forecast Period?

To learn more about this report, Download Report Sample

Market Segmentation

By Product

The market share growth by the combination therapy segment will be significant during the forecast period. Combination therapy involves the use of two or more therapeutic agents for the treatment of a disease. Most of the leading manufacturers in the market have developed a single-dose form by combining 2-3 different types of drug classes for effective treatment. Moreover, combination therapy drugs are novel in the sense that they have multiple pharmacologic effects on the body. During the last decade, various high-efficacy combinations of novel bronchodilators have been approved for the treatment. Such factors will increase segment growth during the forecast period.

Get a glance at the market contribution of various segments View PDF Sample

The combination therapy segment was valued at USD 11.27 billion in 2018. The pipeline is flooded with combination therapy drugs, most of which are in the registration and pre-registration phases of development. For instance, in December 2020, AstraZeneca's Trixeo Aerosphere (formoterol fumarate/glycopyrronium bromide/budesonide) was approved in the European Union (EU) for maintenance treatment in adult patients with moderate-to-severe COPD who are not adequately treated by a combination of an inhaled corticosteroid (ICS) and a long-acting beta2-agonist (LABA). This is the fourth major approval for AstraZeneca's triple-combination therapy, which is marketed as Breztri Aerosphere in the US, China, and Japan. Thus, late-stage pipeline molecules and recent product approval will contribute to the growth of the segment during the forecast period.

By Region

For more insights on the market share of various regions View PDF Sample now!

North America is estimated to contribute 55% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. Market growth in North America can be attributed to three major drivers, namely, the growing incidence of COPD, the availability of reimbursement schemes, and approvals for new triple combination drugs for the treatment of COPD. The rising incidence of COPD is a major driving factor for the market in North America.  As per the National Institutes of Health (NIH), COPD is one of the leading causes of death in the US, and in 2020, it affected 16 million people in the US. Risk factors for COPD, such as smoking and air pollutants, have also been increasing drastically over the past three decades. These factors will facilitate market growth during the forecast period.

Market Dynamics and Customer Landscape

The market is influenced by organizations like the World Health Organisation (WHO) and the Centre for Disease Control and Prevention (CDCP), which highlight the disease burden of COPD. The Global Burden of Disease Study and the Institute of Health Metrics and Evaluation provide insights into its impact on global health. Factors such as tobacco consumption, especially among the youth population, contribute to its prevalence. Expenditure on healthcare is significant, particularly in developing and underdeveloped countries. R&D investment is crucial for developing innovative therapies and treatment approaches to manage COPD and improve outcomes and quality of life. Chronic Obstructive Pulmonary Disease (COPD) drugs and Pulmonary Arterial Hypertension (PAH) drugs are both critical in managing severe respiratory conditions, as they target different aspects of lung and cardiovascular health. These efforts focus on diagnosis, recognition, and the development of diagnostic tools and treatments for COPD, including generic drugs. Addressing smoking tobacco and reducing workplace and indoor air pollution are key strategies for its management. Patients require long-term care and specialized treatment to manage COPD effectively. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Key Market Driver

The increasing prevalence of COPD is accelerating the growth of the market globally. This is a chronic non-communicable lifestyle-related disease that progresses steadily without medical intervention. There are several lifestyle-related factors, such as smoking, exposure to biomass fuel, and air pollution, which increase the risk of developing COPD. Because of the significant prevalence of these factors in the environment worldwide, COPD has become a leading cause of mortality and morbidity globally. As per Natalie Terzikhan et al., COPD is considered the third-leading cause of death worldwide. Smoking is considered the leading cause of COPD, especially in developed countries where cigarette smoking is widespread.

Moreover, tobacco smoke from pipes, cigars, and cigarettes is indeed an irritant that affects the bronchi and the alveoli of the lungs, leading to chronic obstructive pulmonary disease (COPD). Smoking tobacco is a major risk factor for developing COPD, and understanding its effects is crucial for diagnosis and treatment approaches. The symptoms usually appear after 40 years of age. Hence, the growth of the global geriatric population will further increase the number of people at risk. Likewise, rare genetic conditions such as alpha-1 antitrypsin deficiency predispose people to an increased risk. Since alpha-1 antitrypsin is a protein that helps to protect the lungs from damage caused by inflammation, people who do not have this protein are more susceptible to COPD.

Significant Market Trends

Expanding research in curative approaches is the key market trend driving market growth. Considerable research is underway to find the ideal treatment. Researchers identify molecular targets that drive this disease progression. The identification of molecular targets is necessary for the development of new biological therapies, such as monoclonal antibodies, which can target physiological proteins responsible for disease progression.

Although some monoclonal antibodies failed to comply with the regulatory guidelines initially, there are other similar products in the pipeline for COPD. Similarly, some dual and triple-fixed-dose combination drugs are also in the late stages of development, owing to the multiple therapeutic benefits they provide. Apart from fixed-dose combination drugs that have entered the market or are in the registration phase, there are novel small molecular approaches that hold promising potential for the treatment of COPD.

Major Market Challenge

The high cost of COPD clinical trials is a major challenge hindering the growth of the market. The high cost of clinical trials for respiratory diseases is a major challenge for the market. The incidence has increased rapidly in recent years. According to ClinicalTrials.gov, there are few ongoing clinical trials for Diagnostics of respiratory diseases. About 39 studies have been done on COPD. The costs associated with each stage of a clinical trial limit the number of studies that can be conducted in clinical trials.

However, approximately USD115.3 million is spent for each phase of a clinical trial, which includes Phases I, II, III, and IV. Respiratory system studies ranked third in terms of cost spent per study in clinical trials. Therefore, the high cost of conducting clinical trials in respiratory disorders will negatively impact the growth of the global COPD drugs market during the forecast period.

Key Market Customer Landscape

The report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Market Customer Landscape

Who are the Major Market Companies?

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

AstraZeneca - The company offers chronic obstructive pulmonary disease drugs such as Pulmicort Turbuhaler. Also, the company engages in the discovery, development, manufacturing, marketing, and sale of pharmaceutical products.

The market report also includes detailed analyses of the competitive landscape of the market and information about 15 market companies, including:

• Exela Pharma Sciences LLC
• GlaxoSmithKline Plc
• Glenmark Pharmaceuticals Ltd.
• Innoviva Inc.
• Lupin Ltd.
• Merck and Co. Inc.
• Mundipharma International Ltd.
• Novartis AG
• Theravance Biopharma Inc.
• Vertex Pharmaceuticals Inc.
• Viatris Inc.
• Boehringer Ingelheim International GmbH
• Cadila Pharmaceuticals Ltd.
• CHIESI Farmaceutici SpA
• Cipla Ltd.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Segment Overview

The market research report provides comprehensive data (region wise segment analysis), with forecasts and estimates in "USD billion" for the period 2024 to 2028, as well as historical data from 2018 to 2022 for the following segments.  

• Product Outlook 
  • Combination therapy
  • Monotherapy

• Distribution Channel Outlook
  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies

• Region Outlook 
  • North America
    • The U.S.
    • Canada
  • Europe
    • The U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
  • ROW
    • Argentina
    • Austarlia
    • Rest of the world

Market Analyst Overview

The market is influenced by regulatory bodies like the FDA and the availability of generic drugs that can reduce healthcare costs in both developing countries and developed ones. Governments play a crucial role in promoting medical knowledge about COPD and reducing workplace pollution to prevent this chronic disease. COPD is often associated with comorbidities, and improving access to treatment is essential to prevent underdiagnoses and under treatment, ultimately improving patient outcomes.

Furthermore, COPD includes conditions like Chronic bronchitis and Emphysema, affecting the bronchial tubes and often exacerbated by asthma. Risk factors include exposure to chemicals and fumes from burning fuel, with a genetic factor such as alpha-1-antitrypsin deficiency also playing a role. Lifestyle changes like reducing drinking can help manage COPD, especially in developing countries where awareness and government investment in healthcare are crucial. The Pharmaceutical industry's investment in COPD treatments, including biosimilars after patent expiry, can also impact the market.

Get access to Report Sample PDF !

What are the Key Data Covered in this Market Research Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the market growth and forecasting of the market between 2023 and 2027
• Precise estimation of the size of the market size and its contribution to the parent market
• Accurate predictions about upcoming market trends and analysis and changes in consumer behavior
• Growth of the market industry across Europe, North America, APAC, South America, and Middle East and Africa
• Thorough market growth analysis of the market’s competitive landscape and detailed information about companies
• Comprehensive market analysis and report on the factors that will challenge the market research and growth of market companies

We can help! Our analysts can customize this report to meet your requirements. Get in touch